| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
145,981,000 |
| Market
Cap: |
322.62(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.13 - $2.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
25,516 |
25,516 |
25,516 |
| Total Sell Value |
$0 |
$30,379 |
$30,379 |
$30,379 |
| Total People Sold |
0 |
3 |
3 |
3 |
| Total Sell Transactions |
0 |
3 |
3 |
3 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Makhzoumi Mohamad |
10% Owner |
– – • |
2020-12-04 |
4 |
B |
$0.62 |
$2,735,930 |
I/I |
4,398,602 |
6,451,056 |
1.5 |
71% |
|
| Nea 16 Gp, Llc |
10% Owner |
– – • |
2020-12-04 |
4 |
B |
$0.62 |
$2,735,930 |
D/D |
4,398,602 |
6,451,056 |
2.45 |
71% |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2020-12-04 |
4 |
B |
$0.62 |
$2,735,930 |
I/I |
4,398,602 |
6,451,056 |
1.5 |
71% |
|
| Makower Joshua |
10% Owner |
– – • |
2020-12-04 |
4 |
B |
$0.62 |
$2,735,930 |
I/I |
4,398,602 |
6,451,056 |
1.5 |
71% |
|
| Baskett Forest |
10% Owner |
– – • |
2020-12-04 |
4 |
B |
$0.62 |
$2,735,930 |
I/I |
4,398,602 |
6,451,056 |
1.5 |
71% |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2020-11-16 |
4 |
AS |
$0.52 |
$456 |
D/D |
(876) |
25,762 |
|
155% |
|
| Hagan Joseph P |
President and CEO |
• • – |
2020-11-16 |
4 |
AS |
$0.52 |
$3,176 |
D/D |
(6,094) |
215,994 |
|
155% |
|
| Hagan Joseph P |
President and CEO |
• • – |
2020-08-14 |
4 |
AS |
$0.60 |
$2,568 |
D/D |
(4,245) |
222,088 |
|
116% |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2020-08-14 |
4 |
AS |
$0.61 |
$528 |
D/D |
(872) |
26,638 |
|
116% |
|
| Hagan Joseph P |
President and CEO |
• • – |
2020-05-15 |
4 |
AS |
$0.63 |
$2,774 |
D/D |
(4,426) |
226,333 |
|
-28% |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2020-05-15 |
4 |
AS |
$0.63 |
$570 |
D/D |
(909) |
27,510 |
|
-28% |
|
| Sarissa Capital Master Fund Ii Lp |
10% Owner |
– – • |
2020-04-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
76,356 |
|
48% |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2020-02-18 |
4 |
AS |
$0.83 |
$737 |
D/D |
(888) |
28,419 |
|
-12% |
|
| Hagan Joseph P |
President and CEO |
• • – |
2020-02-18 |
4 |
AS |
$0.83 |
$3,591 |
D/D |
(4,324) |
230,759 |
|
-12% |
|
| Rastetter William H |
Director |
– • – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
I/I |
225,940 |
390,584 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
846,320 |
2,039,521 |
|
- |
|
| Hagan Joseph P |
President and CEO |
• • – |
2020-01-02 |
4 |
AS |
$0.97 |
$8,067 |
D/D |
(8,345) |
235,083 |
|
- |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2020-01-02 |
4 |
AS |
$0.97 |
$2,164 |
D/D |
(2,239) |
29,307 |
|
- |
|
| Hagan Joseph P |
President and CEO |
• • – |
2019-10-01 |
4 |
AS |
$0.68 |
$5,969 |
D/D |
(8,743) |
249,266 |
|
- |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2019-10-01 |
4 |
AS |
$0.68 |
$1,602 |
D/D |
(2,346) |
32,379 |
|
- |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2019-08-15 |
4 |
AS |
$0.55 |
$495 |
D/D |
(899) |
34,725 |
|
- |
|
| Hagan Joseph P |
President and CEO |
• • – |
2019-08-15 |
4 |
AS |
$0.55 |
$2,409 |
D/D |
(4,375) |
258,009 |
|
- |
|
| Chevallard Daniel R. |
Chief Financial Officer |
• – – |
2019-07-01 |
4 |
AS |
$1.31 |
$3,500 |
D/D |
(2,669) |
77,870 |
|
- |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2019-07-01 |
4 |
AS |
$1.31 |
$2,918 |
D/D |
(2,225) |
35,624 |
|
- |
|
| Hagan Joseph P |
President and CEO |
• • – |
2019-07-01 |
4 |
AS |
$1.31 |
$7,584 |
D/D |
(5,783) |
262,384 |
|
- |
|
306 Records found
|
|
Page 2 of 13 |
|
|
0.04 (1.78%) 
